Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S I Ertel

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Biomedical Materials Research|August 1, 1994
Evaluation of a series of tyrosine-derived polycarbonates as degradable biomaterialsS I Ertel, J Kohn
Expert Opinion on Investigational Drugs|May 1, 1997
Mibefradil (Ro 40-5967): the first selective T-type Ca2+ channel blockerS I Ertel, J P Clozel
Trends in Pharmacological Sciences|February 1, 1997
Low-voltage-activated T-type Ca2+ channelsS I Ertel, E A Ertel
Journal of Biomedical Materials Research|December 1, 1990
Radiofrequency plasma deposition of oxygen-containing films on polystyrene and poly(ethylene terephthalate) substrates improves endothelial cell growthS I Ertel, B D Ratner, T A Horbett
Proceedings of the Association of American Physicians|October 16, 1999
Voltage-gated T-type Ca2+ channels and heart failureJ P Clozel, E A Ertel, S I Ertel
Journal of Molecular Medicine (Berlin, Germany)|June 3, 1999
Endothelin antagonism with bosentan: a review of potential applicationsS Roux, V Breu, S I Ertel, et al.
Cardiovascular Drugs and Therapy|March 26, 1998
T-type Ca2+ channels and pharmacological blockade: potential pathophysiological relevanceS I Ertel, E A Ertel, J P Clozel
Expert Opinion on Investigational Drugs|July 5, 2005
The pharmacology of bosentanV Breu, S I Ertel, S Roux, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|March 3, 1998
Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blockerJ P Clozel, E A Ertel, S I Ertel
Journal of Biomedical Materials Research|November 1, 1995
Evaluation of poly(DTH carbonate), a tyrosine-derived degradable polymer, for orthopedic applicationsS I Ertel, J Kohn, M C Zimmerman, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Biomedical Materials Research|August 1, 1994
Evaluation of a series of tyrosine-derived polycarbonates as degradable biomaterialsS I Ertel, J Kohn
Expert Opinion on Investigational Drugs|May 1, 1997
Mibefradil (Ro 40-5967): the first selective T-type Ca2+ channel blockerS I Ertel, J P Clozel
Trends in Pharmacological Sciences|February 1, 1997
Low-voltage-activated T-type Ca2+ channelsS I Ertel, E A Ertel
Journal of Biomedical Materials Research|December 1, 1990
Radiofrequency plasma deposition of oxygen-containing films on polystyrene and poly(ethylene terephthalate) substrates improves endothelial cell growthS I Ertel, B D Ratner, T A Horbett
Proceedings of the Association of American Physicians|October 16, 1999
Voltage-gated T-type Ca2+ channels and heart failureJ P Clozel, E A Ertel, S I Ertel
Journal of Molecular Medicine (Berlin, Germany)|June 3, 1999
Endothelin antagonism with bosentan: a review of potential applicationsS Roux, V Breu, S I Ertel, et al.
Cardiovascular Drugs and Therapy|March 26, 1998
T-type Ca2+ channels and pharmacological blockade: potential pathophysiological relevanceS I Ertel, E A Ertel, J P Clozel
Expert Opinion on Investigational Drugs|July 5, 2005
The pharmacology of bosentanV Breu, S I Ertel, S Roux, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|March 3, 1998
Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blockerJ P Clozel, E A Ertel, S I Ertel
Journal of Biomedical Materials Research|November 1, 1995
Evaluation of poly(DTH carbonate), a tyrosine-derived degradable polymer, for orthopedic applicationsS I Ertel, J Kohn, M C Zimmerman, et al.
Pageof 2